美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Apnimed

27.09

+1.535.99%

成交量：55.26萬

成交額：1,490.04萬

市值：11.28億

市盈率：6.95

高：27.96

開：25.81

低：25.66

收：25.56

52周最高：35.29

52周最低：16.12

股本：4,163.08萬

流通股本：1,200.00萬

量比：2.20

換手率：4.60%

股息：- -

股息率：- -

每股收益(TTM):3.90

每股收益(LYR):-23.7581

淨資產收益率：--

總資產收益率：-36.94%

市淨率：-6.40

市盈率(LYR):-1.14

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Apnimed

交易所：

NASDAQ

成立時間：

2017

員工人數：

81

公司地址：

39 John F. Kennedy Street,4th Floor,Cambridge,Massachusetts,United States

官網：

http://www.apnimed.com

郵編：

02138

電話：

傳真：

- -

簡介：

Apnimed, Inc.於2017年6月根據特拉華州法律成立。該公司是一家後期臨床製藥公司，致力於發現、開發和商業化新型口服療法，解決睡眠相關呼吸疾病的神經生物學問題。其唯一的臨床候選產品Oxnimbi是一種研究性固定劑量抗呼吸暫停神經肌肉調節劑，結合新型抗毒蠅鹼和選擇性去甲腎上腺素再攝取抑製劑，旨在通過改善上氣道肌肉活動來治療阻塞性睡眠呼吸暫停，以維持氣道通暢並防止睡眠期間氣道塌陷，並於2026年4月向FDA提交了一份新藥申請。

董事

名稱

職位

Kevin R. Lind

Chief Executive Officer and Director

Chris Dimitropoulos

Independent Director

Gary Sender

Independent Director

Lawrence G. Miller

Director and Vice Chair

Paul Fonteyne

Independent Director

Paul Sekhri

Board Chair and Director

股東

名稱

職位

Kevin R. Lind

Chief Executive Officer and Director

Dennis P. Molnar

Chief Operating Officer and President

Michael Kelly

Chief Financial Officer

Barry Wohl

Chief Business Officer

Beth Weinberg

Chief Regulatory and Safety Officer

Graham Goodrich

Chief Commercial Officer

John Cronin

Chief Medical Officer

Luigi Taranto Montemurro

Chief Scientific Officer

Steven Spector

Chief Legal Officer and Head of Corporate Affairs

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/APMD/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"APMD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APMD\",,,,,undefined,":{"symbol":"APMD","market":"US","secType":"STK","nameCN":"Apnimed","latestPrice":27.09,"timestamp":1789588800000,"preClose":25.56,"halted":0,"volume":552568,"delay":0,"changeRate":0.05985915492957751,"floatShares":12000000,"shares":41630779,"eps":3.898,"marketStatus":"盤前交易","change":1.53,"latestTime":"09-17 06:32:02 EDT","open":25.81,"high":27.96,"low":25.66,"amount":14900398.942072,"amplitude":0.089984,"askPrice":29.5,"askSize":500,"bidPrice":25.02,"bidSize":5,"shortable":3,"etf":0,"ttmEps":3.898,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"listingDate":1785470400000,"exchange":"NASDAQ","adjPreClose":27.09,"postHourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.09,"latestTime":"19:51 EDT","volume":18791,"amount":509102.5376,"timestamp":1789602671754,"change":0.41,"changeRate":0.015135,"amplitude":0.015135},"volumeRatio":2.201452102823596},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APMD\",,,,,undefined,":{"symbol":"APMD","floatShares":12000000,"roa":"-36.94%","roe":"--","lyrEps":-23.758134,"volumeRatio":2.201452102823596,"shares":41630779,"dividePrice":0,"high":27.96,"amplitude":0.089984,"preClose":25.56,"low":25.66,"week52Low":16.12,"pbRate":"-6.40","psRate":"9.80","week52High":35.29,"institutionHeld":0,"latestPrice":27.09,"committee":-0.980198,"eps":3.898,"divideRate":0,"volume":552568,"delay":0,"ttmEps":3.898,"open":25.81,"prevYearClose":16,"prevWeekClose":26.23,"prevMonthClose":26.25,"prevQuarterClose":16,"fiveDayClose":28.08,"twentyDayClose":31.81,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APMD\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APMD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APMD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":4,"updateTime":1787716800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APMD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APMD","date":"2026-09-16","current":6.949718,"percent":0.967742,"low":-12.845073,"twenty":-12.101434,"median":-9.91611,"eighty":-8.036647,"high":6.675359,"avg":-8.754874,"sd":5.215282,"marketCap":1064082711},"quantilePoints":[{"date":"2026-08-07","current":-8.661063,"twenty":-8.320585,"median":-7.986942,"eighty":-7.766377,"marketCap":1110270342},{"date":"2026-08-14","current":-8.943759,"twenty":-8.664791,"median":-8.256435,"eighty":-7.766377,"marketCap":1146509438},{"date":"2026-08-21","current":-12.343549,"twenty":-9.895607,"median":-8.661063,"eighty":-7.942829,"marketCap":1582331874},{"date":"2026-08-28","current":-12.417048,"twenty":-11.890448,"median":-9.403529,"eighty":-8.185761,"marketCap":1591753815},{"date":"2026-09-04","current":-12.023611,"twenty":-12.049552,"median":-9.950282,"eighty":-8.269016,"marketCap":1541318719},{"date":"2026-09-11","current":-8.703457,"twenty":-12.127375,"median":-10.111822,"eighty":-8.343574,"marketCap":1115704877},{"date":"2026-09-16","current":6.504849,"twenty":-12.101434,"median":-9.91611,"eighty":-8.036647,"marketCap":1064082711}],"updateTime":1789641122295},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":573282303,"yearFounded":2017,"employeeNum":81,"address":"39 John F. Kennedy Street,4th Floor,Cambridge,Massachusetts,United States","zipCode":"02138","officePhone":"617 500 8880","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.apnimed.com","stockEarnings":[{"period":"1week","weight":-0.0353},{"period":"1month","weight":-0.1677},{"period":"3month","weight":0.6931},{"period":"ytd","weight":0.6931}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0241},{"period":"3month","weight":0.0098},{"period":"6month","weight":0.1626},{"period":"1year","weight":0.1425},{"period":"ytd","weight":0.1058}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Apnimed, Inc.於2017年6月根據特拉華州法律成立。該公司是一家後期臨床製藥公司，致力於發現、開發和商業化新型口服療法，解決睡眠相關呼吸疾病的神經生物學問題。其唯一的臨床候選產品Oxnimbi是一種研究性固定劑量抗呼吸暫停神經肌肉調節劑，結合新型抗毒蠅鹼和選擇性去甲腎上腺素再攝取抑製劑，旨在通過改善上氣道肌肉活動來治療阻塞性睡眠呼吸暫停，以維持氣道通暢並防止睡眠期間氣道塌陷，並於2026年4月向FDA提交了一份新藥申請。","exchange":"NASDAQ","name":"Apnimed","nameEN":"Apnimed"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"APMD\",market:\"US\",,,undefined,":{"directors":[{"name":"Kevin R. Lind","position":"Chief Executive Officer and Director"},{"name":"Chris Dimitropoulos","position":"Independent Director"},{"name":"Gary Sender","position":"Independent Director"},{"name":"Lawrence G. Miller","position":"Director and Vice Chair"},{"name":"Paul Fonteyne","position":"Independent Director"},{"name":"Paul Sekhri","position":"Board Chair and Director"}],"executives":[{"name":"Kevin R. Lind","position":"Chief Executive Officer and Director"},{"name":"Dennis P. Molnar","position":"Chief Operating Officer and President"},{"name":"Michael Kelly","position":"Chief Financial Officer"},{"name":"Barry Wohl","position":"Chief Business Officer"},{"name":"Beth Weinberg","position":"Chief Regulatory and Safety Officer"},{"name":"Graham Goodrich","position":"Chief Commercial Officer"},{"name":"John Cronin","position":"Chief Medical Officer"},{"name":"Luigi Taranto Montemurro","position":"Chief Scientific Officer"},{"name":"Steven Spector","position":"Chief Legal Officer and Head of Corporate Affairs"}]}}}